Nektar lifted by Merck alliance for bempeg, new trial funding
pharmaphorum
FEBRUARY 18, 2021
Merck will pair Keytruda (pembrolizumab) with bempegaldesleukin (NKTR-214) – known as bempeg for short – in a phase 2/3 trial involving patients with squamous cell carcinoma of the head and neck (SCCHN) that if positive could support regulatory filings. That was signed for $1.8
Let's personalize your content